BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

Development and evaluation of next-generation cardiotoxicity assay based on embryonic stem cell-derived cardiomyocytes
Bokyeong Ryu 1 (Graduate student), Seong Woo Choi2 (Research worker), Seul-Gi Lee2 (Graduate student), Young-Hoon Jeong2 (Graduate student), Ukjin Kim1 (Graduate student), Jin Kim1 (Graduate student), Cho-Rok Jung3 (Research worker), Hyung-Min Chung2 (Professor), Jae-Hak Park1 (Professor), C-Yoon Kim 2,* (Professor)
1Department of Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University,
2Department of Medicine, School of Medicine, Konkuk University,
3Gene Therapy Research Unit, Korea Research Institute of Bioscience and Biotechnology
In accordance with requirements of the ICH S7B safety pharmacology guidelines, numerous next-generation cardiotoxicity studies using human stem cell-derived cardiomyocytes (CMs) are being conducted worldwide. Although several stem cell-derived CMs are being developed for commercialization, there is insufficient research to verify whether these CMs can replace animal experiments. In the present study, in vitro high-efficiency CMs derived from human embryonic stem cells (hESC-CMs) were compared with Sprague-Dawley rats as in vivo experimental animals, and primary cultured in vitro rat-CMs for cardiotoxicity tests. In vivo rats were administrated with 2 consecutive injections of 100 mg/kg isoproterenol, 15 mg/kg doxorubicin, or 100 mg/kg nifedipine, while in vitro rat-CMs and hESC-CMs were treated with 5 レM isoproterenol, 5 レM doxorubicin, and 50 レM nifedipine. We have verified the equivalence of hESC-CMs assessments over various molecular biological markers, morphological analysis. Moreover, we have identified the advantages of hESC-CMs, which can distinguish between species variability, over electrophysiological analysis of ion channels against cardiac damage. Our findings demonstrated the possibility and advantage of high-efficiency hESC-CMs as next-generation cardiotoxicity assessment.
Abstract, Accepted Manuscript(in press) [Submitted on February 3, 2020, Accepted on February 28, 2020]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd